tirzepatide bowel movement Mounjaro (Tirzepatide) & Constipation: The Complete Guide to Relief Managing Tirzepatide Diarrhea: Practical Tips

The paradigm shift that began with EMPA-REG OUTCOME and LEADER has led to SGLT2 inhibitors and GLP-1 RA being recognised not only in international diabetes guidelines, but also as an important consideration for patients with T2D in CVD prevention [28,29,30, 76, 77], HF [133,134,135] and CKD [41, 102] guidelines, where it has been suggested that these agents should be considered early in the course of diabetes management

Research demonstrates that approximately 45% of patients experience meaningful weight reductions at this dose level, though outcomes vary based on individual peptide pathway sensitivity and adherence patterns

39 Furthermore, clinical T2D guidelines emphasize individualized therapy, in which the choice of glucose-lowering therapy should include considerations about glucose-reducing effects, desired weight loss, side effects, costs, and patient preferences

Wegovy and Saxenda, both injectables, are the only GLP-1s FDA-approved for obesity